RxDoctor Payments Data

Joshua Jacobi, MD

Cardiovascular Disease · Pasadena, CANPI 1710109509

Payments from drug & device makers

$950in general payments, 2019–2025

Across 28 payments — averaging $33.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$484
  • Novo Nordisk$205
  • Esperion Therapeutics, Inc.$70
  • Bayer$48
  • Heartflow, Inc.$31
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$31
  • plus $81 from 4 others

What the payments were for

  • Travel & lodging$26928%
  • Food & beverage$66270%
  • Education$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$950 in reported general payments places this provider in the 35th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$305,281
Medicare patients
483
Services billed
2,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban113$93,776
JardianceEmpagliflozin76$62,086
OzempicSemaglutide54$56,536
EntrestoSacubitril/Valsartan58$47,323
Repatha SureclickEvolocumab48$41,117
XareltoRivaroxaban41$32,681
Repatha PushtronexEvolocumab41$26,471
MounjaroTirzepatide23$22,423
Praluent PenAlirocumab31$16,427
VascepaIcosapent Ethyl24$10,886
Losartan Potassium196$2,814
Rosuvastatin Calcium256$2,763
Olmesartan Medoxomil76$2,688
Atorvastatin Calcium243$2,001
Telmisartan85$1,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$205$56,53654 claims
Lilly USA, LLCMounjaro$27$22,42323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →